Business Context and Reporting Period
This Form 10-Q covers the fiscal quarter and nine months ended June 30, 2002, for AmerisourceBergen Corporation (the Company). The Company was formed via the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, consummated on August 29, 2001. Operations are aggregated into two reportable segments: Pharmaceutical Distribution and PharMerica. The financial results for the prior-year periods (ended June 30, 2001) reflect only AmeriSource operations, as the Merger had not yet occurred; therefore, pro forma comparisons are utilized to assess organic growth.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2002 |
Nine Months Ended June 30, 2002 |
|---|---|---|
| Total Revenue | $11,620,827 | $33,633,874 |
| Operating Revenue (excl. bulk) | $10,278,327 | $29,883,212 |
| Gross Profit | $509,929 | $1,495,855 |
| Operating Income | $182,743 | $524,814 |
| Net Income | $90,224 | $249,981 |
| Diluted EPS | $0.82 | $2.30 |
| Cash and Equivalents (End of Period) | $363,406 | $363,406 |
| Net Cash from Operating Activities | N/A | $128,078 |
| Total Debt (Current + Long-term) | $1,538,511 | $1,538,511 |
Margins (Nine Months Ended June 30, 2002):
- Gross Profit Margin: 5.01% of Operating Revenue
- Operating Income Margin: 1.76% of Operating Revenue
- Net Income Margin: 0.84% of Operating Revenue
Material Changes vs. Prior Period
Historical comparisons show massive increases due to the inclusion of Bergen Brunswig operations post-merger. Pro forma comparisons (combining AmeriSource and Bergen for the prior year) provide a clearer view of operational performance:
- Revenue Growth: Operating revenue increased 14% in the quarter and 17% for the nine months on a pro forma basis, driven by the Pharmaceutical Distribution segment.
- Profitability: Operating income (excluding merger costs) increased 16% in the quarter and 19% for the nine months on a pro forma basis.
- Merger Costs: The Company expensed $8.1 million in the quarter and $20.4 million for the nine months related to integration, consulting, and severance.
- Interest Expense: Increased significantly to $27.3 million (quarter) and $91.0 million (nine months) due to higher debt levels associated with the Merger, though variable rates decreased.
- Segment Performance:
- Pharmaceutical Distribution: Revenue up 14% (quarter) and 17% (nine months) pro forma. Gross margin declined slightly due to customer mix shifts and competitive pricing.
- PharMerica: Revenue up 11% (quarter) and 8% (nine months) pro forma. Operating income improved due to expense ratio reductions in the workers' compensation business.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- Integration Synergies: The Company expects to achieve approximately $150 million in annual synergies by the end of the third year following the Merger through facility consolidation (reducing distribution centers from 51 to ~30) and administrative efficiencies.
- Merger Costs: Total merger costs for the fiscal year ending September 30, 2002, are expected to be between $25 million and $30 million.
- Capital Expenditures: Expected to be approximately $60 million to $70 million for the fiscal year.
- Industry Growth: Industry growth rates are estimated to be in the low teens over the next year.
Risks and Contingencies:
- Legal Matters: Pending antitrust actions (largely dismissed or settled), environmental remediation liabilities (approx. $0.9 million accrued), and Proposition 65 litigation regarding coal tar and lead/cadmium warnings (settlement discussions ongoing).
- PharMerica Litigation: Securities class actions and potential liability related to Medicare billing by former nursing home clients (Sensitive Care bankruptcy case).
- Market Risk: Exposure to interest rate fluctuations on variable-rate debt ($355 million outstanding). A 36 basis-point increase would raise annual interest expense by $0.36 million per $100 million of debt.
- Subsequent Event: On July 15, 2002, the Company acquired AutoMed Technologies for $120 million cash, with potential contingent payments up to $55 million.
Investor Verification Checklist
- Pro Forma Comparability: Verify that all year-over-year growth analysis utilizes the pro forma figures provided, as historical 2001 data excludes Bergen Brunswig.
- Merger Integration Progress: Monitor the execution of facility closures and the realization of the projected $150 million in annual synergies.
- Debt Refinancing: Confirm the refinancing of the $150 million 7 3/8% senior notes due in January 2003, which are currently classified as long-term based on intent to refinance.
- Legal Resolutions: Track the status of the Proposition 65 settlement and the PharMerica Medicare billing liability.
- AutoMed Acquisition: Review the purchase price allocation and integration of AutoMed Technologies following the July 2002 acquisition.